SBIR/STTR Research Award

Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

Award identifier 628001d0ff98c509507b7dd93867b44854246532cd3c5545947718c5d2886925Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$121,978

Program and phase

STTR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
EscaZyme Biochemicals, LLC
Proposal award date
2017-09-30
Contract end date
2018-09-29
UEI
Not reported
Solicitation number
PA16-303
Topic code
N

Research abstract

Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostly overseas The purity and reliability of these sources is highly variable A synthetic source for lutein would ensure quality and secure adequate supplies for the predicted ever increasing demand for this eye health product However there is no commercially viable synthesis of the natural enantiomerically correct form R andapos R andapos R of lutein This barrier prevents the development of a secure reliable and scalable source for lutein Furthermore the unavailability of pure synthetic isomers prevents definitive experimental studies on their relative effectiveness The current proposal seeks to remove this barrier by demonstrating a reliable synthesis of enantiomerically correct lutein and zeaxanthin The hypothesis is that highly enantiomerically enriched S ipsdienol or R ipsdienol can be used to synthesize nature identical lutein or zeaxanthin respectively We have developed an innovative enzymatic process that eliminates the current prohibitively high cost to produce enantiomerically enriched ipsdienol Furthermore we will optimize production of recombinant enzymes used in our process further reducing costs Completion of this Phase I project will show the practicality of new production methods for lutein and zeaxanthin This should lead to significant price reductions for highly pure forms of these chemicals thus enabling further research into their protective properties Phase II efforts will confirm the bioactivity of our products and confirm that possible contaminants in natural preparations do not confer the protective effects assigned to lutein and zeaxanthin We will also seek to expand the potential market for these chemicals as food supplements Project Narrative Lutein and zeaxanthin are recommended as dietary supplements for people at risk of developing late onset macular degeneration AMD The proposed research will investigate the feasibility of a new method to synthesize pure lutein isomers from scratch creating both a valuable research tool as well as a potential alternative source of nature identical lutein and zeaxanthin

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.